Pharmaceuticals News

The pharmaceuticals news email from Wiser has been specifically designed for anyone with an interest in the industry. This includes medical practitioners, investors and those involved in research and development. By its very nature, the pharmaceutical industry is subject to constant change. It is a research-driven industry with companies spending much of their revenues developing new medicines and vaccines. As a result patients are able to get new and more effective treatments. This is helping to increase the life expectancy of individuals in most countries. But there are challenges. The costs of the research and development can be large which puts up the price of drugs, while governments and the medical industry argue to try to keep prices as low as possible. The industry also faces challenges from alternatives, both legal (through generic drugs) and illegal (through black market economies). To follow the latest developments in this industry you should sign up for the pharmaceuticals news email from Wiser. It is the best way to find must-read articles on the topic from around the web.

Recent Pharmaceuticals News Coverage
 
Your Weekly Recommendations Saturday, February 25, 2017
 
Recommended for you
Drug importation won't save dollars or lives
The Hill • Opinion Contributor, Sally C. Pipes
Is AEterna Zentaris Worth A Look?
Seeking Alpha • Biotech Beast
Three Global private equity funds vie for 25% stake in Indegene
The Economic Times of India • Sneha Shah
The Growing Conflict-of-Interest Problem in the U.S. Congress
Harvard Business Review • Amy Ingram
Synergy: 3 Scenarios, 1 Choice
Seeking Alpha • Strategydoc
European advisory committee positive actions
Seeking Alpha • Seeking Alpha
India's Pharma Barons Are Reporting Delays in Digitizing Labs
Bloomberg • Ari Altstedter
Should We Invest In Biotech Now?
Seeking Alpha • Kenra Investors
Zogenix Is On The Precipice Of Substantial Growth
Seeking Alpha • Tim Harrison
These Were the 10 Biggest Pharmaceutical Deals of 2016
Fortune Magazine • Sy Mukherjee
 
Recommended for You
Barack Obama, Pharmaceuticals
Drug importation won't save dollars or lives
The HillOpinion Contributor, Sally C. Pipes
A recent oped in by MedShadow Foundation founder Suzanne Robotti claims that permitting Americans to import prescription drugs from Canada would save dollars and lives. It would do neither. Prescription drug importation has several notable proponents, like Sens. John McCain (R-Ariz.), Amy...
Share
Cancer, Epidemiology
Is AEterna Zentaris Worth A Look?
Seeking AlphaBiotech Beast
Summary AEZS could achieve positive feedback from the FDA in 2017 regarding macimorelin. Due to low cash reserves, the market might not respond positively to any eventual marketing approval. A binary event, which cannot be reliably predicted, approaches in April with phase...
Share
Finance, Hedge Funds
Three Global private equity funds vie for 25% stake in Indegene
The Economic Times of IndiaSneha Shah
MUMBAI: Global private equity funds TA Associates, Kedaara Capital and Apax Partners are in the race to acquire around 25% stake in Indegene, a healthcare IT firm backed by InfosysBSE 1.73 % cofounder NS Raghavan. The company, which has $75 million, or...
Share
Finance, Investment Industry
The Growing Conflict-of-Interest Problem in the U.S. Congress
Harvard Business ReviewAmy Ingram
While concerns about conflicts of interest regarding President Trump’s business holdings have received a lot of attention, resulting in proposed legislation to end loopholes for the commander in chief, there has been much less discussion of another source of conflicting interests: the...
Share
Health Finance, Pharmaceuticals
Synergy: 3 Scenarios, 1 Choice
Seeking AlphaStrategydoc
Summary Synergy has a recently FDA approved product (Trulance) to be used by patients with chronic idiopathic constipation (CIC). It may soon offer an sNDA for irritable bowel syndrome, constipation (IBS-C). Last week Synergy offered additional discussion of the pending commercialization effort...
Share
Novartis AG, Pfizer, Inc.
European advisory committee positive actions
Seeking AlphaSeeking Alpha
The European Medicines Agency's Committee for Medical Products for Human Use (CHMP) is churning out recommendations today. Positive opinions: Expanded use of Novartis' (NYSE:NVS) Mekinist (trametinib) and Tafinlar (debrafenib) in advanced NSCLC with BRAF V600 mutation. Expanded use of Gilead Sciences' (NASDAQ:GILD)...
Share
Pharmaceuticals
India's Pharma Barons Are Reporting Delays in Digitizing Labs
BloombergAri Altstedter
Heads of two of India’s largest drug makers said integration of electronic systems to prevent quality lapses in factories is going slower than expected, as the industry looks to adapt to increased scrutiny from regulators in the developed world that have resulted...
Share
Biotechnology, Health Finance
Should We Invest In Biotech Now?
Seeking AlphaKenra Investors
Summary After a steep decline occurred between 2015 and 2016, biotech is trading at a significant discount to the market. The sector started to decline in 2015 during the China crash, but kept performing poorly as a result of fears of price...
Share
Health Finance, Pharmaceuticals
Zogenix Is On The Precipice Of Substantial Growth
Seeking AlphaTim Harrison
Summary The company has a promising drug candidate in late stage trials. Zogenix has several upcoming catalysts in 2017. The company's lead product candidate targets an unmet need for the treatment of a devastating childhood condition. Introduction Zogenix Inc., (NASDAQ:ZGNX), is a...
Share
Biotechnology, Health Care Industry
These Were the 10 Biggest Pharmaceutical Deals of 2016
Fortune MagazineSy Mukherjee
Last year was, well, not the greatest for the drug industry. A contentious presidential election where both candidates slammed the biopharma industry, with a healthy assist from a cast of cartoonish, price-gouging villains, marred the entire sector (the NASDAQ Biotech Index fell...
Share